United Therapeutics: From Niche Player to Giant in Organ Technology

With the excellent study data from March 30, 2026, United Therapeutics is on the brink of tapping into the billion-dollar market of idiopathic pulmonary fibrosis and massively expanding its dominance in pulmonology. The company leverages its high cash flows from the established treprostinil business for aggressive stock buybacks and the financing of revolutionary technologies such as xenotransplantation and 3D bioprinting of organs. United Therapeutics is transforming from a pure biotech player into a visionary organ technology corporation,...